Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Connect Biopharma’s IL-4Rα Antibody Effective in Atopic Dermatitis Patients

publication date: Mar 20, 2023

Taicang Connect Biopharma said its IL-4Rα antibody met endpoints in early data from an ongoing pivotal China trial for moderate-to-severe atopic dermatitis (AD). The company reported that CBP-201, a next-gen IL-4Rα antibody, showed rapid relief from symptoms, as early as week one in some cases, without hitting an efficacy plateau at Week 16. Connect develops T cell therapies for inflammatory diseases. CBP-201, the company’s lead candidate, has shown efficacy for treating AD in four body regions: head and neck, trunk, upper limbs and lower limbs. More details....

Stock Symbol: (NSDQ: CNTB)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital